Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: Clin Cancer Res. 2019 Apr 15;25(13):3784–3792. doi: 10.1158/1078-0432.CCR-18-3502

Table 2.

Adverse events regardless of relationship to study treatment (occurring in > 20% of treated patients, N=11)

Maximum grade
Adverse Event 1 2 3 4 Total
N (%) N (%) N (%) N (%) N (%)
Diarrhea 5 (45%) 3 (27%) 1 (9%) 0 (0%) 9 (82%)
Nausea 3 (27%) 3 (27%) 1 (9%) 0 (0%) 7 (64%)
vomiting 0 (0%) 6 (55%) 1 (9%) 0 (0%) 7 (64%)
Abdominal pain 4 (36%) 1 (9%) 0 (0%) 0 (0%) 5 (45%)
Anorexia 2 (18%) 2 (18%) 0 (0%) 0 (0%) 4 (36%)
Headache 4 (36%) 0 (0%) 0 (0%) 0 (0%) 4 (36%)
PPE 3 (27%) 1 (9%) 1 (9%) 0 (0%) 5 (45%)
Peripheral neuropathy 2 (18%) 1 (9%) 0 (0%) 0 (0%) 3 (27%)
Fatigue 4 (36%) 3 (27%) 0 (0%) 0 (0%) 7 (64%)
Generated muscle weakness 0 (0%) 2 (18%) 1 (9%) 0 (0%) 3 (27%)
Back pain 2 (18%) 1 (9%) 0 (0%) 0 (0%) 3 (27%)

N, number of patients, PPE, Palmar-plantar erythrodysesthesia